Immuneering (IMRX) Research & Development (2020 - 2023)
Historic Research & Development for Immuneering (IMRX) over the last 4 years, with Q4 2023 value amounting to $11.9 million.
- Immuneering's Research & Development rose 2064.9% to $11.9 million in Q4 2023 from the same period last year, while for Dec 2023 it was $41.6 million, marking a year-over-year increase of 1474.5%. This contributed to the annual value of $41.6 million for FY2023, which is 1477.07% up from last year.
- Latest data reveals that Immuneering reported Research & Development of $11.9 million as of Q4 2023, which was up 2064.9% from $10.1 million recorded in Q3 2023.
- Immuneering's Research & Development's 5-year high stood at $11.9 million during Q4 2023, with a 5-year trough of $3.2 million in Q2 2020.
- In the last 4 years, Immuneering's Research & Development had a median value of $8.0 million in 2022 and averaged $7.8 million.
- Its Research & Development has fluctuated over the past 5 years, first skyrocketed by 11707.44% in 2021, then soared by 732.99% in 2023.
- Over the past 4 years, Immuneering's Research & Development (Quarter) stood at $4.9 million in 2020, then skyrocketed by 62.57% to $8.0 million in 2021, then rose by 24.17% to $9.9 million in 2022, then rose by 20.65% to $11.9 million in 2023.
- Its Research & Development was $11.9 million in Q4 2023, compared to $10.1 million in Q3 2023 and $9.5 million in Q2 2023.